Cardiac effects of HDL and its components on diabetic cardiomyopathy

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 12, Issue 2, 2012, Pages 132-147

  Spillmann, Frank ^a   van Linthout, Sophie ^a   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Diabetes mellitus; Dysfunction; Endothelial dysfunction; Glucose metabolism; High density lipoprotein; Remodeling

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIOXIDANT; CALCIUM ION; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR BI; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; ENDOTHELIAL DYSFUNCTION; FIBROSIS; GLUCOSE HOMEOSTASIS; HEART; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INFLAMMATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SARCOPLASMIC RETICULUM;

ANIMALS; ANTIOXIDANTS; CALCIUM; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; LIPOPROTEINS, HDL; MALE; MICE; RATS;

EID: 84861121923     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/187153012800493521     Document Type: Review

References (225)

1. King, H.; Aubert, R.E. and Herman, W.H. (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 21, 1414-1431.
2. Amos, A.F.; McCarty, D.J. and Zimmet, P. (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med., 14 Suppl 5, S1-85.
3. Kannel, W.B. and McGee, D.L. (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA, 241, 2035-2038.
4. Iribarren, C.; Karter, A.J.; Go, A.S.; Ferrara, A.; Liu, J.Y.; Sidney, S. and Selby, J.V. (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation, 103, 2668-2673.
5. Stratton, I.M.; Adler, A.I.; Neil, H.A.; Matthews, D.R.; Manley, S.E.; Cull, C.A.; Hadden, D.; Turner, R.C. and Holman, R.R. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321, 405-412.
6. Rubler, S.; Dlugash, J.; Yuceoglu, Y.Z.; Kumral, T.; Branwood, A.W. and Grishman, A. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol., 30, 595-602.
7. Cosson, S. and Kevorkian, J.P. (2003) Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab., 29, 455-466.
8. Davidson, M.B. (2003) Metabolic syndrome/insulin resistance syndrome/pre-diabetes: new section in diabetes care. Diabetes Care, 26, 3179.
9. Freire, C.M.; Moura, A.L.; Barbosa Mde, M.; Machado, L.J.; Nogueira, A.I. and Ribeiro-Oliveira Jr, A. (2007) Left ventricle diastolic dysfunction in diabetes: an update. Arq. Bras. Endocrinol. Metabol., 51, 168-175.
10. Gordon, T.; Castelli, W.P.; Hjortland, M.C.; Kannel, W.B. and Dawber, T.R. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med., 62, 707-714.
11. Rubins, H.B.; Robins, S.J.; Collins, D.; Fye, C.L.; Anderson, J.W.; Elam, M.B.; Faas, F.H.; Linares, E.; Schaefer, E.J.; Schectman, G.; Wilt, T.J. and Wittes, J. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 341, 410-418.
12. Mackness, M.I. and Durrington, P.N. (1995) HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis, 115, 243-253.
13. Sugano, M.; Tsuchida, K. and Makino, N. (2000) High-density lipoproteins protect endothelial cells from tumor necrosis factoralpha-induced apoptosis. Biochem. Biophys. Res. Commun., 272, 872-876.
14. Cockerill, G.W.; Huehns, T.Y.; Weerasinghe, A.; Stocker, C.; Lerch, P.G.; Miller, N.E. and Haskard, D.O. (2001) Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation, 103, 108-112.
15. Van Linthout, S.; Foryst-Ludwig, A.; Spillmann, F.; Peng, J.; Feng, Y.; Meloni, M.; Van Craeyveld, E.; Kintscher, U.; Schultheiss, H.P.; De Geest, B. and Tschope, C. Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis, 210, 438-444.
16. Ansell, B.J.; Navab, M.; Hama, S.; Kamranpour, N.; Fonarow, G.; Hough, G.; Rahmani, S.; Mottahedeh, R.; Dave, R.; Reddy, S.T. and Fogelman, A.M. (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation, 108, 2751-2756.
17. Levkau, B.; Hermann, S.; Theilmeier, G.; van der Giet, M.; Chun, J.; Schober, O. and Schafers, M. (2004) High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation, 110, 3355-3359.
18. Calabresi, L.; Rossoni, G.; Gomaraschi, M.; Sisto, F.; Berti, F. and Franceschini, G. (2003) High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ. Res., 92, 330-337.
19. Theilmeier, G.; Schmidt, C.; Herrmann, J.; Keul, P.; Schafers, M.; Herrgott, I.; Mersmann, J.; Larmann, J.; Hermann, S.; Stypmann, J.; Schober, O.; Hildebrand, R.; Schulz, R.; Heusch, G.; Haude, M.; von Wnuck Lipinski, K.; Herzog, C.; Schmitz, M.; Erbel, R.; Chun, J. and Levkau, B. (2006) High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation, 114, 1403-1409.
20. Van Linthout, S.; Spillmann, F.; Riad, A.; Trimpert, C.; Lievens, J.; Meloni, M.; Escher, F.; Filenberg, E.; Demir, O.; Li, J.; Shakibaei, M.; Schimke, I.; Staudt, A.; Felix, S.B.; Schultheiss, H.P.; De Geest, B. and Tschope, C. (2008) Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation, 117, 1563-1573.
21. Tilton, R.G.; Daugherty, A.; Sutera, S.P.; Larson, K.B.; Land, M.P.; Rateri, D.L.; Kilo, C. and Williamson, J.R. (1989) Myocyte contracture, vascular resistance, and vascular permeability after global ischemia in isolated hearts from alloxan-induced diabetic rabbits. Diabetes, 38, 1484-1491.
22. Tao, R.; Hoover, H.E.; Honbo, N.; Kalinowski, M.; Alano, C.C.; Karliner, J.S. and Raffai, R. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am. J. Physiol. Heart Circ. Physiol., 298, H1022-1028.
23. Baroukh, N.; Lopez, C.E.; Saleh, M.C.; Recalde, D.; Vergnes, L.; Ostos, M.A.; Fiette, L.; Fruchart, J.C.; Castro, G.; Zakin, M.M. and Ochoa, A. (2004) Expression and secretion of human apolipoprotein A-I in the heart. FEBS Lett., 557, 39-44.
24. Zannis, V.I.; Cole, F.S.; Jackson, C.L.; Kurnit, D.M. and Karathanasis, S.K. (1985) Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages. Biochemistry, 24, 4450-4455.
25. Vetter, R.; Rehfeld, U.; Reissfelder, C.; Weiss, W.; Wagner, K.D.; Gunther, J.; Hammes, A.; Tschöpe, C.; Dillmann, W. and Paul, M. (2002) Transgenic overexpression of the sarcoplasmic reticulum Ca2+ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB J., 16, 1657-1659.
26. Tschope, C.; Walther, T.; Koniger, J.; Spillmann, F.; Westermann, D.; Escher, F.; Pauschinger, M.; Pesquero, J.B.; Bader, M.; Schultheiss, H.P. and Noutsias, M. (2004) Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J., 18, 828-835.
27. Tschope, C.; Spillmann, F.; Rehfeld, U.; Koch, M.; Westermann, D.; Altmann, C.; Dendorfer, A.; Walther, T.; Bader, M.; Paul, M.; Schultheiss, H.P. and Vetter, R. (2004) Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J., 18, 1967-1969.
28. Tschope, C.; Walther, T.; Escher, F.; Spillmann, F.; Du, J.; Altmann, C.; Schimke, I.; Bader, M.; Sanchez-Ferrer, C.F.; Schultheiss, H.P. and Noutsias, M. (2005) Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J., 19, 2057-2059.
29. Rodrigues, B.; Cam, M.C. and McNeill, J.H. (1998) Metabolic disturbances in diabetic cardiomyopathy. Mol. Cell Biochem., 180, 53-57.
30. Westermann, D.; Van Linthout, S.; Dhayat, S.; Dhayat, N.; Schmidt, A.; Noutsias, M.; Song, X.Y.; Spillmann, F.; Riad, A.; Schultheiss, H.P. and Tschope, C. (2007) Tumor necrosis factoralpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res. Cardiol., 102, 500-507.
31. Westermann, D.; Van Linthout, S.; Dhayat, S.; Dhayat, N.; Escher, F.; Bucker-Gartner, C.; Spillmann, F.; Noutsias, M.; Riad, A.; Schultheiss, H.P. and Tschope, C. (2007) Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes, 56, 1834-1841.
32. Rota, M.; LeCapitaine, N.; Hosoda, T.; Boni, A.; De Angelis, A.; Padin-Iruegas, M.E.; Esposito, G.; Vitale, S.; Urbanek, K.; Casarsa, C.; Giorgio, M.; Luscher, T.F.; Pelicci, P.G.; Anversa, P.; Leri, A. and Kajstura, J. (2006) Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ. Res., 99, 42-52.
33. Young, M.E.; McNulty, P. and Taegtmeyer, H. (2002) Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation, 105, 1861-1870.
34. Zhou, Y.T.; Grayburn, P.; Karim, A.; Shimabukuro, M.; Higa, M.; Baetens, D.; Orci, L. and Unger, R.H. (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA, 97, 1784-1789.
35. Devereux, R.B.; Roman, M.J.; Paranicas, M.; O'Grady, M.J.; Lee, E.T.; Welty, T.K.; Fabsitz, R.R.; Robbins, D.; Rhoades, E.R. and Howard, B.V. (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation, 101, 2271-2276.
36. Cai, L.; Li, W.; Wang, G.; Guo, L.; Jiang, Y. and Kang, Y.J. (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes, 51, 1938-1948.
37. Nishikawa, T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P.; Giardino, I. and Brownlee, M. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404, 787-790.
38. Cai, H. (2005) NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ. Res., 96, 818-822.
39. Hink, U.; Li, H.; Mollnau, H.; Oelze, M.; Matheis, E.; Hartmann, M.; Skatchkov, M.; Thaiss, F.; Stahl, R.A.; Warnholtz, A.; Meinertz, T.; Griendling, K.; Harrison, D.G.; Forstermann, U. and Munzel, T. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res., 88, E14-22.
40. Du, X.; Matsumura, T.; Edelstein, D.; Rossetti, L.; Zsengeller, Z.; Szabo, C. and Brownlee, M. (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest., 112, 1049-1057.
41. Brownlee, M.; Cerami, A. and Vlassara, H. (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318, 1315-1321.
42. Candido, R.; Forbes, J.M.; Thomas, M.C.; Thallas, V.; Dean, R.G.; Burns, W.C.; Tikellis, C.; Ritchie, R.H.; Twigg, S.M.; Cooper, M.E. and Burrell, L.M. (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res., 92, 785-792.
43. Brownlee, M. (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 54, 1615-1625.
44. Aronson, D. (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens., 21, 3-12.
45. Simm, A.; Bartling, B. and Silber, R.E. (2004) RAGE: a new pleiotropic antagonistic gene? Ann. N. Y. Acad. Sci., 1019, 228-231.
46. Li, S.Y.; Sigmon, V.K.; Babcock, S.A. and Ren, J. (2007) Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci., 80, 1051-1056.
47. Aragno, M.; Mastrocola, R.; Alloatti, G.; Vercellinatto, I.; Bardini, P.; Geuna, S.; Catalano, M.G.; Danni, O. and Boccuzzi, G. (2008) Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology, 149, 380-388.
48. Zhou, G.; Li, C. and Cai, L. (2004) Advanced glycation endproducts induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor betaindependent pathway. Am. J. Pathol., 165, 2033-2043.
49. 263-272.
50. Schmidt, A.M.; Hori, O.; Chen, J.X.; Li, J.F.; Crandall, J.; Zhang, J.; Cao, R.; Yan, S.D.; Brett, J. and Stern, D. (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest., 96, 1395-1403.
51. Basta, G.; Lazzerini, G.; Massaro, M.; Simoncini, T.; Tanganelli, P.; Fu, C.; Kislinger, T.; Stern, D.M.; Schmidt, A.M. and De Caterina, R. (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation, 105, 816-822.
52. Kunt, T.; Forst, T.; Harzer, O.; Buchert, G.; Pfutzner, A.; Lobig, M.; Zschabitz, A.; Stofft, E.; Engelbach, M. and Beyer, J. (1998) The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp. Clin. Endocrinol. Diabetes, 106, 183-188.
53. Zhou, Y.J.; Wang, J.H. and Zhang, J. (2006) Hepatocyte growth factor protects human endothelial cells against advanced glycation end products-induced apoptosis. Biochem. Biophys. Res. Commun., 344, 658-666.
54. Riad, A.; Westermann, D.; Van Linthout, S.; Mohr, Z.; Uyulmaz, S.; Becher, P.M.; Rutten, H.; Wohlfart, P.; Peters, H.; Schultheiss, H.P. and Tschope, C. (2008) Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes. Diabetologia, 51, 2325-2332.
55. Brouwers, O.; Niessen, P.M.; Haenen, G.; Miyata, T.; Brownlee, M.; Stehouwer, C.D.; De Mey, J.G. and Schalkwijk, C.G. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia, 53, 989-1000.
56. Ma, H.; Li, S.Y.; Xu, P.; Babcock, S.A.; Dolence, E.K.; Brownlee, M.; Li, J. and Ren, J. (2009) Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J. Cell. Mol. Med., 13, 1751-1764.
57. Petrova, R.; Yamamoto, Y.; Muraki, K.; Yonekura, H.; Sakurai, S.; Watanabe, T.; Li, H.; Takeuchi, M.; Makita, Z.; Kato, I.; Takasawa, S.; Okamoto, H.; Imaizumi, Y. and Yamamoto, H. (2002) Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J. Mol. Cell. Cardiol., 34, 1425-1431.
58. Hart, G.W.; Housley, M.P. and Slawson, C. (2007) Cycling of Olinked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature, 446, 1017-1022.
59. Baker, D.L.; Dave, V.; Reed, T. and Periasamy, M. (1996) Multiple Sp1 binding sites in the cardiac/slow twitch muscle sarcoplasmic reticulum Ca2+-ATPase gene promoter are required for expression in Sol8 muscle cells. J. Biol. Chem., 271, 5921-5928.
60. Clark, R.J.; McDonough, P.M.; Swanson, E.; Trost, S.U.; Suzuki, M.; Fukuda, M. and Dillmann, W.H. (2003) Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J. Biol. Chem., 278, 44230-44237.
61. Hu, Y.; Belke, D.; Suarez, J.; Swanson, E.; Clark, R.; Hoshijima, M. and Dillmann, W.H. (2005) Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ. Res., 96, 1006-1013.
62. Katare, R.G.; Caporali, A.; Oikawa, A.; Meloni, M.; Emanueli, C. and Madeddu, P. Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ. Heart Fail., 3, 294-305.
63. Hasuike, Y.; Nakanishi, T.; Otaki, Y.; Nanami, M.; Tanimoto, T.; Taniguchi, N. and Takamitsu, Y. (2002) Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am. J. Kidney Dis., 40, 464-471.
64. Yan, S.F.; Ramasamy, R.; Naka, Y. and Schmidt, A.M. (2003) Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ. Res., 93, 1159-1169.
65. Nakamura, N.; Obayashi, H.; Fujii, M.; Fukui, M.; Yoshimori, K.; Ogata, M.; Hasegawa, G.; Shigeta, H.; Kitagawa, Y.; Yoshikawa, T.; Kondo, M.; Ohta, M.; Nishimura, M.; Nishinaka, T. and Nishimura, C.Y. (2000) Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic. Biol. Med., 29, 17-25.
66. Tang, W.H.; Cheng, W.T.; Kravtsov, G.M.; Tong, X.Y.; Hou, X.Y.; Chung, S.K. and Chung, S.S. Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am. J. Physiol. Cell. Physiol., 299, C643-653.
67. Tang, W.H.; Kravtsov, G.M.; Sauert, M.; Tong, X.Y.; Hou, X.Y.; Wong, T.M.; Chung, S.K. and Man Chung, S.S. Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins. J. Mol. Cell. Cardiol., 49, 58-69.
68. Toth, E.; Racz, A.; Toth, J.; Kaminski, P.M.; Wolin, M.S.; Bagi, Z. and Koller, A. (2007) Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH(2)/TXA(2) mediation. Am. J. Physiol. Heart Circ. Physiol., 293, H3096-3104.
69. Ramana, K.V.; Bhatnagar, A. and Srivastava, S.K. (2004) Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J., 18, 1209-1218.
70. Ramana, K.V.; Friedrich, B.; Srivastava, S.; Bhatnagar, A. and Srivastava, S.K. (2004) Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes, 53, 2910-2920.
71. Ramana, K.V.; Friedrich, B.; Tammali, R.; West, M.B.; Bhatnagar, A. and Srivastava, S.K. (2005) Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes, 54, 818-829.
72. Ding, Y.; Vaziri, N.D.; Coulson, R.; Kamanna, V.S. and Roh, D.D. (2000) Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am. J. Physiol. Endocrinol. Metab., 279, E11-17.
73. Inoguchi, T.; Li, P.; Umeda, F.; Yu, H.Y.; Kakimoto, M.; Imamura, M.; Aoki, T.; Etoh, T.; Hashimoto, T.; Naruse, M.; Sano, H.; Utsumi, H. and Nawata, H. (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 49, 1939-1945.
74. Cosentino, F.; Eto, M.; De Paolis, P.; van der Loo, B.; Bachschmid, M.; Ullrich, V.; Kouroedov, A.; Delli Gatti, C.; Joch, H.; Volpe, M. and Luscher, T.F. (2003) High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation, 107, 1017-1023.
75. Xia, P.; Aiello, L.P.; Ishii, H.; Jiang, Z.Y.; Park, D.J.; Robinson, G.S.; Takagi, H.; Newsome, W.P.; Jirousek, M.R. and King, G.L. (1996) Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest., 98, 2018-2026.
76. Quagliaro, L.; Piconi, L.; Assaloni, R.; Da Ros, R.; Maier, A.; Zuodar, G. and Ceriello, A. (2005) Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis, 183, 259-267.
77. Connelly, K.A.; Kelly, D.J.; Zhang, Y.; Prior, D.L.; Advani, A.; Cox, A.J.; Thai, K.; Krum, H. and Gilbert, R.E. (2009) Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ. Heart. Fail., 2, 129-137.
78. Davidoff, A.J.; Davidson, M.B.; Carmody, M.W.; Davis, M.E. and Ren, J. (2004) Diabetic cardiomyocyte dysfunction and myocyte insulin resistance: role of glucose-induced PKC activity. Mol. Cell. Biochem., 262, 155-163.
79. Geraldes, P. and King, G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res., 106, 1319-1331.
80. Arikawa, E.; Ma, R.C.; Isshiki, K.; Luptak, I.; He, Z.; Yasuda, Y.; Maeno, Y.; Patti, M.E.; Weir, G.C.; Harris, R.A.; Zammit, V.A.; Tian, R. and King, G.L. (2007) Effects of insulin replacements, inhibitors of angiotensin, and PKCbeta's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes, 56, 1410-1420.
81. Sharma, S.; Guthrie, P.H.; Chan, S.S.; Haq, S. and Taegtmeyer, H. (2007) Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc. Res., 76, 71-80.
82. McMullen, J.R.; Shioi, T.; Huang, W.Y.; Zhang, L.; Tarnavski, O.; Bisping, E.; Schinke, M.; Kong, S.; Sherwood, M.C.; Brown, J.; Riggi, L.; Kang, P.M. and Izumo, S. (2004) The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem., 279, 4782-4793.
83. Crackower, M.A.; Oudit, G.Y.; Kozieradzki, I.; Sarao, R.; Sun, H.; Sasaki, T.; Hirsch, E.; Suzuki, A.; Shioi, T.; Irie-Sasaki, J.; Sah, R.; Cheng, H.Y.; Rybin, V.O.; Lembo, G.; Fratta, L.; Oliveira-dos-Santos, A.J.; Benovic, J.L.; Kahn, C.R.; Izumo, S.; Steinberg, S.F.; Wymann, M.P.; Backx, P.H. and Penninger, J.M. (2002) Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell, 110, 737-749.
84. Condorelli, G.; Drusco, A.; Stassi, G.; Bellacosa, A.; Roncarati, R.; Iaccarino, G.; Russo, M.A.; Gu, Y.; Dalton, N.; Chung, C.; Latronico, M.V.; Napoli, C.; Sadoshima, J.; Croce, C.M. and Ross, J. Jr. (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. USA, 99, 12333-12338.
85. Shiojima, I.; Yefremashvili, M.; Luo, Z.; Kureishi, Y.; Takahashi, A.; Tao, J.; Rosenzweig, A.; Kahn, C.R.; Abel, E.D. and Walsh, K. (2002) Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J. Biol. Chem., 277, 37670-37677.
86. Morisco, C.; Condorelli, G.; Trimarco, V.; Bellis, A.; Marrone, C.; Sadoshima, J. and Trimarco, B. (2005) Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ. Res., 96, 180-188.
87. Shimizu, I.; Minamino, T.; Toko, H.; Okada, S.; Ikeda, H.; Yasuda, N.; Tateno, K.; Moriya, J.; Yokoyama, M.; Nojima, A.; Koh, G.Y.; Akazawa, H.; Shiojima, I.; Kahn, C.R.; Abel, E.D. and Komuro, I. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin. Invest., 120, 1506-1514.
88. Armoni, M.; Harel, C.; Bar-Yoseph, F.; Milo, S. and Karnieli, E. (2005) Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements. J. Biol. Chem., 280, 34786-34795.
89. Luiken, J.J.; Arumugam, Y.; Dyck, D.J.; Bell, R.C.; Pelsers, M.M.; Turcotte, L.P.; Tandon, N.N.; Glatz, J.F. and Bonen, A. (2001) Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J. Biol. Chem., 276, 40567-40573.
90. Sakamoto, J.; Barr, R.L.; Kavanagh, K.M. and Lopaschuk, G.D. (2000) Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am. J. Physiol. Heart. Circ. Physiol., 278, H1196-1204.
91. Hickson-Bick, D.L.; Buja, L.M. and McMillin, J.B. (2000) Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J. Mol. Cell. Cardiol., 32, 511-519.
92. Zhang, D.X.; Fryer, R.M.; Hsu, A.K.; Zou, A.P.; Gross, G.J.; Campbell, W.B. and Li, P.L. (2001) Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res. Cardiol., 96, 267-274.
93. Liu, G.X.; Hanley, P.J.; Ray, J. and Daut, J. (2001) Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K(ATP) channels in the heart. Circ. Res., 88, 918-924.
94. Hammer, S.; Snel, M.; Lamb, H.J.; Jazet, I.M.; van der Meer, R.W.; Pijl, H.; Meinders, E.A.; Romijn, J.A.; de Roos, A. and Smit, J.W. (2008) Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J. Am. Coll. Cardiol., 52, 1006-1012.
95. Viljanen, A.P.; Karmi, A.; Borra, R.; Parkka, J.P.; Lepomaki, V.; Parkkola, R.; Lautamaki, R.; Jarvisalo, M.; Taittonen, M.; Ronnemaa, T.; Iozzo, P.; Knuuti, J.; Nuutila, P. and Raitakari, O.T. (2009) Effect of caloric restriction on myocardial fatty acid uptake, left ventricular mass, and cardiac work in obese adults. Am. J. Cardiol., 103, 1721-1726.
96. Krauss, R.M. and Nichols, A.V. (1986) Metabolic interrelationships of HDL subclasses. Adv. Exp. Med. Biol., 201, 17-27.
97. Li, Z.; McNamara, J.R.; Ordovas, J.M. and Schaefer, E.J. (1994) Analysis of high density lipoproteins by a modified gradient gel electrophoresis method. J. Lipid. Res., 35, 1698-1711.
98. Johansson, J.; Carlson, L.A.; Landou, C. and Hamsten, A. (1991) High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler. Thromb., 11, 174-182.
99. Freedman, D.S.; Otvos, J.D.; Jeyarajah, E.J.; Barboriak, J.J.; Anderson, A.J. and Walker, J.A. (1998) Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 18, 1046-1053.
100. Pascot, A.; Lemieux, I.; Bergeron, J.; Tremblay, A.; Nadeau, A.; Prud'homme, D.; Couillard, C.; Lamarche, B. and Despres, J.P. (2002) HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis, 160, 399-406.
101. Johnson, J.L.; Slentz, C.A.; Duscha, B.D.; Samsa, G.P.; McCartney, J.S.; Houmard, J.A. and Kraus, W.E. (2004) Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis, 176, 371-377.
102. Gordon, D.J.; Probstfield, J.L.; Garrison, R.J.; Neaton, J.D.; Castelli, W.P.; Knoke, J.D.; Jacobs, D.R., Jr.; Bangdiwala, S. and Tyroler, H.A. (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79, 8-15.
103. Feng, Y.; van Eck, M.; Van Craeyveld, E.; Jacobs, F.; Carlier, V.; Van Linthout, S.; Erdel, M.; Tjwa, M. and De Geest, B. (2009) Critical role of scavenger receptor-BI-expressing bone marrowderived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood, 113, 755-764.
104. Wiesner, P.; Leidl, K.; Boettcher, A.; Schmitz, G. and Liebisch, G. (2009) Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid. Res., 50, 574-585.
105. Chun, J.; Goetzl, E.J.; Hla, T.; Igarashi, Y.; Lynch, K.R.; Moolenaar, W.; Pyne, S. and Tigyi, G. (2002) International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev., 54, 265-269.
106. Ishii, I.; Fukushima, N.; Ye, X. and Chun, J. (2004) Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem., 73, 321-354.
107. Persegol, L.; Verges, B.; Foissac, M.; Gambert, P. and Duvillard, L. (2006) Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endotheliumdependent vasorelaxation. Diabetologia, 49, 1380-1386.
108. Sorrentino, S.A.; Besler, C.; Rohrer, L.; Meyer, M.; Heinrich, K.; Bahlmann, F.H.; Mueller, M.; Horvath, T.; Doerries, C.; Heinemann, M.; Flemmer, S.; Markowski, A.; Manes, C.; Bahr, M.J.; Haller, H.; von Eckardstein, A.; Drexler, H. and Landmesser, U. (2010) Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation, 121, 110-122.
109. Zheng, L.; Nukuna, B.; Brennan, M.L.; Sun, M.; Goormastic, M.; Settle, M.; Schmitt, D.; Fu, X.; Thomson, L.; Fox, P.L.; Ischiropoulos, H.; Smith, J.D.; Kinter, M. and Hazen, S.L. (2004) Apolipoprotein A-I is a selective target for myeloperoxidasecatalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest., 114, 529-541.
110. Hedrick, C.C.; Thorpe, S.R.; Fu, M.X.; Harper, C.M.; Yoo, J.; Kim, S.M.; Wong, H. and Peters, A.L. (2000) Glycation impairs high-density lipoprotein function. Diabetologia, 43, 312-320.
111. Matsunaga, T.; Iguchi, K.; Nakajima, T.; Koyama, I.; Miyazaki, T.; Inoue, I.; Kawai, S.; Katayama, S.; Hirano, K.; Hokari, S. and Komoda, T. (2001) Glycated high-density lipoprotein induces apoptosis of endothelial cells via a mitochondrial dysfunction. Biochem. Biophys. Res. Commun., 287, 714-720.
112. Nobecourt, E.; Davies, M.J.; Brown, B.E.; Curtiss, L.K.; Bonnet, D.J.; Charlton, F.; Januszewski, A.S.; Jenkins, A.J.; Barter, P.J. and Rye, K.A. (2007) The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia, 50, 643-653.
113. Forte, T.M.; Oda, M.N.; Knoff, L.; Frei, B.; Suh, J.; Harmony, J.A.; Stuart, W.D.; Rubin, E.M. and Ng, D.S. (1999) Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J. Lipid. Res., 40, 1276-1283.
114. Mastorikou, M.; Mackness, B.; Liu, Y. and Mackness, M. (2008) Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet. Med., 25, 1049-1055.
115. Davidsson, P.; Hulthe, J.; Fagerberg, B.; Olsson, B.M.; Hallberg, C.; Dahllof, B. and Camejo, G. (2005) A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J. Lipid. Res., 46, 1999-2006.
116. Artl, A.; Marsche, G.; Lestavel, S.; Sattler, W. and Malle, E. (2000) Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler. Thromb. Vasc. Biol., 20, 763-772.
117. Kontush, A. and Chapman, M.J. (2006) Antiatherogenic small, dense HDL--guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med., 3, 144-153.
118. Roehrich, M.E.; Mooser, V.; Lenain, V.; Herz, J.; Nimpf, J.; Azhar, S.; Bideau, M.; Capponi, A.; Nicod, P.; Haefliger, J.A. and Waeber, G. (2003) Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J. Biol. Chem., 278, 18368-18375.
119. Rutti, S.; Ehses, J.A.; Sibler, R.A.; Prazak, R.; Rohrer, L.; Georgopoulos, S.; Meier, D.T.; Niclauss, N.; Berney, T.; Donath, M.Y. and von Eckardstein, A. (2009) Low-and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology, 150, 4521-4530.
120. Donath, M.Y.; Storling, J.; Maedler, K. and Mandrup-Poulsen, T. (2003) Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med., 81, 455-470.
121. Abderrahmani, A.; Niederhauser, G.; Favre, D.; Abdelli, S.; Ferdaoussi, M.; Yang, J.Y.; Regazzi, R.; Widmann, C. and Waeber, G. (2007) Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised lowdensity lipoprotein particles in pancreatic beta cells. Diabetologia, 50, 1304-1314.
122. Fryirs, M.A.; Barter, P.J.; Appavoo, M.; Tuch, B.E.; Tabet, F.; Heather, A.K. and Rye, K.A. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler. Thromb. Vasc. Biol., 30, 1642-1648.
123. Han, R.; Lai, R.; Ding, Q.; Wang, Z.; Luo, X.; Zhang, Y.; Cui, G.; He, J.; Liu, W. and Chen, Y. (2007) Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia, 50, 1960-1968.
124. Drew, B.G.; Duffy, S.J.; Formosa, M.F.; Natoli, A.K.; Henstridge, D.C.; Penfold, S.A.; Thomas, W.G.; Mukhamedova, N.; de Courten, B.; Forbes, J.M.; Yap, F.Y.; Kaye, D.M.; van Hall, G.; Febbraio, M.A.; Kemp, B.E.; Sviridov, D.; Steinberg, G.R. and Kingwell, B.A. (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation, 119, 2103-2111.
125. Rapizzi, E.; Taddei, M.L.; Fiaschi, T.; Donati, C.; Bruni, P. and Chiarugi, P. (2009) Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor. Cell. Mol. Life Sci., 66, 3207-3218.
126. Weisberg, S.P.; Hunter, D.; Huber, R.; Lemieux, J.; Slaymaker, S.; Vaddi, K.; Charo, I.; Leibel, R.L. and Ferrante, A.W. Jr. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest., 116, 115-124.
127. Krakoff, J.; Funahashi, T.; Stehouwer, C.D.; Schalkwijk, C.G.; Tanaka, S.; Matsuzawa, Y.; Kobes, S.; Tataranni, P.A.; Hanson, R.L.; Knowler, W.C. and Lindsay, R.S. (2003) Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care, 26, 1745-1751.
128. Matsushita, K.; Yatsuya, H.; Tamakoshi, K.; Wada, K.; Otsuka, R.; Takefuji, S.; Sugiura, K.; Kondo, T.; Murohara, T. and Toyoshima, H. (2006) Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler. Thromb. Vasc. Biol., 26, 871-876.
129. Lindsay, R.S.; Funahashi, T.; Hanson, R.L.; Matsuzawa, Y.; Tanaka, S.; Tataranni, P.A.; Knowler, W.C. and Krakoff, J. (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet, 360, 57-58.
130. Yatagai, T.; Nagasaka, S.; Taniguchi, A.; Fukushima, M.; Nakamura, T.; Kuroe, A.; Nakai, Y. and Ishibashi, S. (2003) Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism, 52, 1274-1278.
131. Daimon, M.; Oizumi, T.; Saitoh, T.; Kameda, W.; Hirata, A.; Yamaguchi, H.; Ohnuma, H.; Igarashi, M.; Tominaga, M. and Kato, T. (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care, 26, 2015-2020.
132. Berg, A.H.; Combs, T.P.; Du, X.; Brownlee, M. and Scherer, P.E. (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med., 7, 947-953.
133. Tomas, E.; Tsao, T.S.; Saha, A.K.; Murrey, H.E.; Zhang Cc, C.; Itani, S.I.; Lodish, H.F. and Ruderman, N.B. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA, 99, 16309-16313.
134. Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.; Waki, H.; Uchida, S.; Yamashita, S.; Noda, M.; Kita, S.; Ueki, K.; Eto, K.; Akanuma, Y.; Froguel, P.; Foufelle, F.; Ferre, P.; Carling, D.; Kimura, S.; Nagai, R.; Kahn, B.B. and Kadowaki, T. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med., 8, 1288-1295.
135. Stefan, N.; Vozarova, B.; Funahashi, T.; Matsuzawa, Y.; Weyer, C.; Lindsay, R.S.; Youngren, J.F.; Havel, P.J.; Pratley, R.E.; Bogardus, C. and Tataranni, P.A. (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes, 51, 1884-1888.
136. Youngren, J.F.; Goldfine, I.D. and Pratley, R.E. (1997) Decreased muscle insulin receptor kinase correlates with insulin resistance in normoglycemic Pima Indians. Am. J. Physiol., 273, E276-283.
137. Zietz, B.; Herfarth, H.; Paul, G.; Ehling, A.; Muller-Ladner, U.; Scholmerich, J. and Schaffler, A. (2003) Adiponectin represents an independent cardiovascular risk factor predicting serum HDLcholesterol levels in type 2 diabetes. FEBS Lett., 545, 103-104.
138. Schulze, M.B.; Rimm, E.B.; Shai, I.; Rifai, N. and Hu, F.B. (2004) Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care, 27, 1680-1687.
139. Cnop, M.; Havel, P.J.; Utzschneider, K.M.; Carr, D.B.; Sinha, M.K.; Boyko, E.J.; Retzlaff, B.M.; Knopp, R.H.; Brunzell, J.D. and Kahn, S.E. (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459-469.
140. Cote, M.; Mauriege, P.; Bergeron, J.; Almeras, N.; Tremblay, A.; Lemieux, I. and Despres, J.P. (2005) Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J. Clin. Endocrinol. Metab., 90, 1434-1439.
141. Verges, B.; Petit, J.M.; Duvillard, L.; Dautin, G.; Florentin, E.; Galland, F. and Gambert, P. (2006) Adiponectin is an important determinant of apoA-I catabolism. Arterioscler. Thromb. Vasc. Biol., 26, 1364-1369.
142. von Eynatten, M.; Hamann, A.; Twardella, D.; Nawroth, P.P.; Brenner, H. and Rothenbacher, D. (2006) Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin. Chem., 52, 853-859.
143. Tschritter, O.; Fritsche, A.; Thamer, C.; Haap, M.; Shirkavand, F.; Rahe, S.; Staiger, H.; Maerker, E.; Haring, H. and Stumvoll, M. (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 52, 239-243.
144. Baratta, R.; Amato, S.; Degano, C.; Farina, M.G.; Patane, G.; Vigneri, R. and Frittitta, L. (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J. Clin. Endocrinol. Metab., 89, 2665-2671.
145. Samaha, F.F.; Szapary, P.O.; Iqbal, N.; Williams, M.M.; Bloedon, L.T.; Kochar, A.; Wolfe, M.L. and Rader, D.J. (2006) Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 26, 624-630.
146. de Souza, J.A.; Vindis, C.; Hansel, B.; Negre-Salvayre, A.; Therond, P.; Serrano, C.V. Jr.; Chantepie, S.; Salvayre, R.; Bruckert, E.; Chapman, M.J. and Kontush, A. (2008) Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis, 197, 84-94.
147. Catalano, G.; Julia, Z.; Frisdal, E.; Vedie, B.; Fournier, N.; Le Goff, W.; Chapman, M.J. and Guerin, M. (2009) Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler. Thromb. Vasc. Biol., 29, 268-275.
148. Peterson, S.J.; Drummond, G.; Kim, D.H.; Li, M.; Kruger, A.L.; Ikehara, S. and Abraham, N.G. (2008) L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J. Lipid. Res., 49, 1658-1669.
149. Peterson, S.J.; Kim, D.H.; Li, M.; Positano, V.; Vanella, L.; Rodella, L.F.; Piccolomini, F.; Puri, N.; Gastaldelli, A.; Kusmic, C.; L'Abbate, A. and Abraham, N.G. (2009) The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J. Lipid. Res., 50, 1293-1304.
150. Hyka, N.; Dayer, J.M.; Modoux, C.; Kohno, T.; Edwards, C.K., 3rd; Roux-Lombard, P. and Burger, D. (2001) Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood, 97, 2381-2389.
151. Gruaz, L.; Delucinge-Vivier, C.; Descombes, P.; Dayer, J.M. and Burger, D. Blockade of T cell contact-activation of human monocytes by high-density lipoproteins reveals a new pattern of cytokine and inflammatory genes. PLoS One, 5, e9418.
152. Carpintero, R.; Gruaz, L.; Brandt, K.J.; Scanu, A.; Faille, D.; Combes, V.; Grau, G.E. and Burger, D. HDL interfere with the binding of T cell microparticles to human monocytes to inhibit proinflammatory cytokine production. PLoS One, 5, e11869.
153. Kim, K.D.; Lim, H.Y.; Lee, H.G.; Yoon, D.Y.; Choe, Y.K.; Choi, I.; Paik, S.G.; Kim, Y.S.; Yang, Y. and Lim, J.S. (2005) Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem. Biophys. Res. Commun., 338, 1126-1136.
154. Coronado, M.T.; Pozzi, A.O.; Punchard, M.A.; Gonzalez, P. and Fantidis, P. (2009) Inflammation as a modulator of the HDL cholesterol-induced inteleukin-10 production by human circulating mononuclear cells. Atherosclerosis, 202, 183-184.
155. Cockerill, G.W.; Rye, K.A.; Gamble, J.R.; Vadas, M.A. and Barter, P.J. (1995) High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol., 15, 1987-1994.
156. Murphy, A.J.; Woollard, K.J.; Hoang, A.; Mukhamedova, N.; Stirzaker, R.A.; McCormick, S.P.; Remaley, A.T.; Sviridov, D. and Chin-Dusting, J. (2008) High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol., 28, 2071-2077.
157. Van Linthout, S.; Spillmann, F.; Schultheiss, H.P. and Tschope, C. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr. Pharm. Des., 16, 1504-1516.
158. Theilmeier, G.; De Geest, B.; Van Veldhoven, P.P.; Stengel, D.; Michiels, C.; Lox, M.; Landeloos, M.; Chapman, M.J.; Ninio, E.; Collen, D.; Himpens, B. and Holvoet, P. (2000) HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J., 14, 2032-2039.
159. Navab, M.; Imes, S.S.; Hama, S.Y.; Hough, G.P.; Ross, L.A.; Bork, R.W.; Valente, A.J.; Berliner, J.A.; Drinkwater, D.C.; Laks, H. and et al. (1991) Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest., 88, 2039-2046.
160. Whetzel, A.M.; Bolick, D.T.; Srinivasan, S.; Macdonald, T.L.; Morris, M.A.; Ley, K. and Hedrick, C.C. (2006) Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ. Res., 99, 731-739.
161. Wilhelm, A.J.; Zabalawi, M.; Owen, J.S.; Shah, D.; Grayson, J.M.; Major, A.S.; Bhat, S.; Gibbs, D.P., Jr.; Thomas, M.J. and Sorci-Thomas, M.G. (2010) Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/-mice. J. Biol. Chem., 285, 36158-36169.
162. He, S.; Li, M.; Ma, X.; Lin, J. and Li, D. (2010) CD4+CD25+ Foxp3+ regulatory T cells protect the proinflammatory activation of human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol., 30, 2621-2630.
163. Sugatani, J.; Miwa, M.; Komiyama, Y. and Ito, S. (1996) Highdensity lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J. Lipid. Mediat. Cell Signal., 13, 73-88.
164. Tselepis, A.D. and John Chapman, M. (2002) Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoproteinassociated phospholipase A2, platelet activating factoracetylhydrolase. Atheroscler. Suppl., 3, 57-68.
165. Liu, M. and Subbaiah, P.V. (1994) Hydrolysis and transesterification of platelet-activating factor by lecithin-cholesterol acyltransferase. Proc. Natl. Acad. Sci. USA, 91, 6035-6039.
166. Rodrigo, L.; Mackness, B.; Durrington, P.N.; Hernandez, A. and Mackness, M.I. (2001) Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J., 354, 1-7.
167. Oak, J.H. and Cai, H. (2007) Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes, 56, 118-126.
168. Westermann, D.; Rutschow, S.; Jager, S.; Linderer, A.; Anker, S.; Riad, A.; Unger, T.; Schultheiss, H.P.; Pauschinger, M. and Tschope, C. (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes, 56, 641-646.
169. Van Linthout, S.; Spillmann, F.; Lorenz, M.; Meloni, M.; Jacobs, F.; Egorova, M.; Stangl, V.; De Geest, B.; Schultheiss, H.P. and Tschope, C. (2009) Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension, 53, 682-687.
170. Tolle, M.; Pawlak, A.; Schuchardt, M.; Kawamura, A.; Tietge, U.J.; Lorkowski, S.; Keul, P.; Assmann, G.; Chun, J.; Levkau, B.; van der Giet, M. and Nofer, J.R. (2008) HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler. Thromb. Vasc. Biol., 28, 1542-1548.
171. Ohtsu, H.; Suzuki, H.; Nakashima, H.; Dhobale, S.; Frank, G.; Motley, E. and Eguchi, S. (2006) Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension, 48, 534-540.
172. Li, D.; Saldeen, T.; Romeo, F. and Mehta, J.L. (2000) Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation, 102, 1970-1976.
173. Gragasin, F.S.; Xu, Y.; Arenas, I.A.; Kainth, N. and Davidge, S.T. (2003) Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 23, 38-44.
174. De Geest, B.; Stengel, D.; Landeloos, M.; Lox, M.; Le Gat, L.; Collen, D.; Holvoet, P. and Ninio, E. (2000) Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo Edeficient mice on 2 lipoprotein-associated enzymes, plateletactivating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler. Thromb. Vasc. Biol., 20, E68-75.
175. Kruger, A.L.; Peterson, S.; Turkseven, S.; Kaminski, P.M.; Zhang, F.F.; Quan, S.; Wolin, M.S. and Abraham, N.G. (2005) D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation, 111, 3126-3134.
176. Westermann, D.; Rutschow, S.; Van Linthout, S.; Linderer, A.; Bucker-Gartner, C.; Sobirey, M.; Riad, A.; Pauschinger, M.; Schultheiss, H.P. and Tschope, C. (2006) Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia, 49, 2507-2513.
177. Suzuki, K.; Murtuza, B.; Sammut, I.A.; Latif, N.; Jayakumar, J.; Smolenski, R.T.; Kaneda, Y.; Sawa, Y.; Matsuda, H. and Yacoub, M.H. (2002) Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemiareperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation, 106, I270-276.
178. Shen, X.; Zheng, S.; Metreveli, N.S. and Epstein, P.N. (2006) Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes, 55, 798-805.
179. Dewald, O.; Frangogiannis, N.G.; Zoerlein, M.; Duerr, G.D.; Klemm, C.; Knuefermann, P.; Taffet, G.; Michael, L.H.; Crapo, J.D.; Welz, A. and Entman, M.L. (2003) Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc. Natl. Acad. Sci. USA, 100, 2700-2705.
180. Wang, W.; Xu, H.; Shi, Y.; Nandedkar, S.; Zhang, H.; Gao, H.; Feroah, T.; Weihrauch, D.; Schulte, M.L.; Jones, D.W.; Jarzembowski, J.; Sorci-Thomas, M. and Pritchard, K.A. Jr. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J. Lipid. Res., 51, 2560-2570.
181. Ou, J.; Wang, J.; Xu, H.; Ou, Z.; Sorci-Thomas, M.G.; Jones, D.W.; Signorino, P.; Densmore, J.C.; Kaul, S.; Oldham, K.T. and Pritchard, K.A., Jr. (2005) Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ. Res., 97, 1190-1197.
182. Bellosta, S.; Gomaraschi, M.; Canavesi, M.; Rossoni, G.; Monetti, M.; Franceschini, G. and Calabresi, L. (2006) Inhibition of MMP-2 activation and release as a novel mechanism for HDL-induced cardioprotection. FEBS Lett., 580, 5974-5978.
183. Van Linthout, S.; Seeland, U.; Riad, A.; Eckhardt, O.; Hohl, M.; Dhayat, N.; Richter, U.; Fischer, J.W.; Bohm, M.; Pauschinger, M.; Schultheiss, H.P. and Tschope, C. (2008) Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic. Res. Cardiol., 103, 319-327.
184. Pauschinger, M.; Knopf, D.; Petschauer, S.; Doerner, A.; Poller, W.; Schwimmbeck, P.L.; Kuhl, U. and Schultheiss, H.P. (1999) Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation, 99, 2750-2756.
185. Spinale, F.G.; Holzgrefe, H.H.; Mukherjee, R.; Hird, R.B.; Walker, J.D.; Arnim-Barker, A.; Powell, J.R. and Koster, W.H. (1995) Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. Circulation, 92, 562-578.
186. Thomas, C.V.; Coker, M.L.; Zellner, J.L.; Handy, J.R.; Crumbley, A.J., 3rd and Spinale, F.G. (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation, 97, 1708-1715.
187. Coker, M.L.; Zellner, J.L.; Crumbley, A.J. and Spinale, F.G. (1999) Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy. Ann. N. Y. Acad. Sci., 878, 559-562.
188. Spinale, F.G.; Coker, M.L.; Bond, B.R. and Zellner, J.L. (2000) Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc. Res., 46, 225-238.
189. Rutschow, S.; Li, J.; Schultheiss, H.P. and Pauschinger, M. (2006) Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc. Res., 69, 646-656.
190. Seeland, U.; Kouchi, I.; Zolk, O.; Itter, G.; Linz, W. and Bohm, M. (2002) Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J. Mol. Cell. Cardiol., 34, 151-163.
191. Seeland, U.; Selejan, S.; Engelhardt, S.; Muller, P.; Lohse, M.J. and Bohm, M. (2007) Interstitial remodeling in beta1-adrenergic receptor transgenic mice. Basic Res. Cardiol., 102, 183-193.
192. Wang, B.; Hao, J.; Jones, S.C.; Yee, M.S.; Roth, J.C. and Dixon, I.M. (2002) Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am. J. Physiol. Heart Circ. Physiol., 282, H1685-1696.
193. Benamer, N.; Fares, N.; Bois, P. and Faivre, J.F. Electrophysiological and functional effects of sphingosine-1-phosphate in mouse ventricular fibroblasts. Biochem. Biophys. Res. Commun., 408, 6-11.
194. Gellings Lowe, N.; Swaney, J.S.; Moreno, K.M. and Sabbadini, R.A. (2009) Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc. Res., 82, 303-312.
195. Sun, H.Y.; Wei, S.P.; Xu, R.C.; Xu, P.X. and Zhang, W.C. Sphingosine-1-phosphate induces human endothelial VEGF and MMP-2 production via transcription factor ZNF580: novel insights into angiogenesis. Biochem. Biophys. Res. Commun., 395, 361-366.
196. Frias, M.A.; Lang, U.; Gerber-Wicht, C. and James, R.W. Native and reconstituted HDL protect cardiomyocytes from doxorubicininduced apoptosis. Cardiovasc. Res., 85, 118-126.
197. Rossoni, G.; Gomaraschi, M.; Berti, F.; Sirtori, C.R.; Franceschini, G. and Calabresi, L. (2004) Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. J. Pharmacol. Exp. Ther., 308, 79-84.
198. Aoyama, T.; Yui, Y.; Morishita, H. and Kawai, C. (1990) Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation, 81, 1784-1791.
199. Zacharowski, K.; Olbrich, A.; Piper, J.; Hafner, G.; Kondo, K. and Thiemermann, C. (1999) Selective activation of the prostanoid EP(3) receptor reduces myocardial infarct size in rodents. Arterioscler. Thromb. Vasc. Biol., 19, 2141-2147.
200. Shinomiya, S.; Naraba, H.; Ueno, A.; Utsunomiya, I.; Maruyama, T.; Ohuchida, S.; Ushikubi, F.; Yuki, K.; Narumiya, S.; Sugimoto, Y.; Ichikawa, A. and Oh-ishi, S. (2001) Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem. Pharmacol., 61, 1153-1160.
201. Zhang, Y.; Peng, T.; Zhu, H.; Zheng, X.; Zhang, X.; Jiang, N.; Cheng, X.; Lai, X.; Shunnar, A.; Singh, M.; Riordan, N.; Bogin, V.; Tong, N. and Min, W.P. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J. Transl. Med., 8, 133.
202. Van Linthout, S.; Spillmann, F.; Graiani, G.; Miteva, K.; Peng, J.; Van Craeyveld, E.; Meloni, M.; Tolle, M.; Escher, F.; Subasiguller, A.; Doehner, W.; Quaini, F.; De Geest, B.; Schultheiss, H.P. and Tschope, C. Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation. J. Mol. Med., 89, 151-160.
203. Sumi, M.; Sata, M.; Miura, S.; Rye, K.A.; Toya, N.; Kanaoka, Y.; Yanaga, K.; Ohki, T.; Saku, K. and Nagai, R. (2007) Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol., 27, 813-818.
204. Yoon, Y.S.; Uchida, S.; Masuo, O.; Cejna, M.; Park, J.S.; Gwon, H.C.; Kirchmair, R.; Bahlman, F.; Walter, D.; Curry, C.; Hanley, A.; Isner, J.M. and Losordo, D.W. (2005) Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation, 111, 2073-2085.
205. Tauber, J.P.; Cheng, J. and Gospodarowicz, D. (1980) Effect of high and low density lipoproteins on proliferation of cultured bovine vascular endothelial cells. J. Clin. Invest., 66, 696-708.
206. Tamagaki, T.; Sawada, S.; Imamura, H.; Tada, Y.; Yamasaki, S.; Toratani, A.; Sato, T.; Komatsu, S.; Akamatsu, N.; Yamagami, M.; Kobayashi, K.; Kato, K.; Yamamoto, K.; Shirai, K.; Yamada, K.; Higaki, T.; Nakagawa, K.; Tsuji, H. and Nakagawa, M. (1996) Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis, 123, 73-82.
207. Radojkovic, C.; Genoux, A.; Pons, V.; Combes, G.; de Jonge, H.; Champagne, E.; Rolland, C.; Perret, B.; Collet, X.; Terce, F. and Martinez, L.O. (2009) Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation. Arterioscler. Thromb. Vasc. Biol., 29, 1125-1130.
208. Murugesan, G.; Sa, G. and Fox, P.L. (1994) High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. Circ. Res., 74, 1149-1156.
209. Kimura, T.; Sato, K.; Malchinkhuu, E.; Tomura, H.; Tamama, K.; Kuwabara, A.; Murakami, M. and Okajima, F. (2003) High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol., 23, 1283-1288.
210. Tso, C.; Martinic, G.; Fan, W.H.; Rogers, C.; Rye, K.A. and Barter, P.J. (2006) High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol., 26, 1144-1149.
211. Feng, Y.; Jacobs, F.; Van Craeyveld, E.; Brunaud, C.; Snoeys, J.; Tjwa, M.; Van Linthout, S. and De Geest, B. (2008) Human ApoAI transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol., 28, 278-283.
212. Suc, I.; Escargueil-Blanc, I.; Troly, M.; Salvayre, R. and Negre-Salvayre, A. (1997) HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol., 17, 2158-2166.
213. Nofer, J.R.; Levkau, B.; Wolinska, I.; Junker, R.; Fobker, M.; von Eckardstein, A.; Seedorf, U. and Assmann, G. (2001) Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem., 276, 34480-34485.
214. Darbon, J.M.; Tournier, J.F.; Tauber, J.P. and Bayard, F. (1986) Possible role of protein phosphorylation in the mitogenic effect of high density lipoproteins on cultured vascular endothelial cells. J. Biol. Chem., 261, 8002-8008.
215. Seetharam, D.; Mineo, C.; Gormley, A.K.; Gibson, L.L.; Vongpatanasin, W.; Chambliss, K.L.; Hahner, L.D.; Cummings, M.L.; Kitchens, R.L.; Marcel, Y.L.; Rader, D.J. and Shaul, P.W. (2006) High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res., 98, 63-72.
216. Strunk, D. (2011) Endothelial progenitor cells: quod erat demonstrandum? Curr. Pharm. Design, 17, 3245-3251.
217. Feng, Y.; Gordts, S.C.; Chen, F.; Hu, Y.; Van Craeyveld, E.; Jacobs, F.; Carlier, V.; Zhang, Z.; Xu, Q.; Ni, Y. and De Geest, B. Topical HDL administration reduces vein graft atherosclerosis in apo E deficient mice. Atherosclerosis, 214, 271-278.
218. Walter, D.H.; Rochwalsky, U.; Reinhold, J.; Seeger, F.; Aicher, A.; Urbich, C.; Spyridopoulos, I.; Chun, J.; Brinkmann, V.; Keul, P.; Levkau, B.; Zeiher, A.M.; Dimmeler, S. and Haendeler, J. (2007) Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler. Thromb. Vasc. Biol., 27, 275-282.
219. Feng, Y.; Van Craeyveld, E.; Jacobs, F.; Lievens, J.; Snoeys, J. and De Geest, B. (2009) Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. J. Mol. Med. (Berl)., 87, 287-297.
220. Guns, P.J.; Van Assche, T.; Verreth, W.; Fransen, P.; Mackness, B.; Mackness, M.; Holvoet, P. and Bult, H. (2008) Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with preexisting atherosclerosis. Br. J. Pharmacol., 153, 508-516.
221. Mochizuki, S.; Okumura, M.; Tanaka, F.; Sato, T.; Kagami, A.; Tada, N. and Nagano, M. (1991) Ischemia-reperfusion arrhythmias and lipids: effect of human high-and low-density lipoproteins on reperfusion arrhythmias. Cardiovasc. Drugs Ther., 5 (Suppl 2), 269-276.
222. Weis, M.T. and Malik, K.U. (1985) Beta adrenergic receptorstimulated prostaglandin synthesis in the isolated rabbit heart: relationship to extra-and intracellular calcium. J. Pharmacol. Exp. Ther., 235, 178-185.
223. Klein, A.L.; Wold, L.E. and Ren, J. (2004) The cyclooxygenase-2 product prostaglandin E2 modulates cardiac contractile function in adult rat ventricular cardiomyocytes. Pharmacol. Res., 49, 99-103.
224. Yew, S.F.; Reeves, K.A. and Woodward, B. (1998) Effects of prostaglandin F2 alpha on intracellular pH, intracellular calcium, cell shortening and L-type calcium currents in rat myocytes. Cardiovasc. Res., 40, 538-545.
225. Ng, K.M.; Lee, Y.K.; Lai, W.H.; Chan, Y.C.; Fung, M.L.; Tse, H.F. and Siu, C.W. Exogenous expression of human apoA-I enhances cardiac differentiation of pluripotent stem cells. PLoS One, 6, e19787.